ATHENA HPV trial

https://www.hpv16and18.com/hcp/athena-hpv-clinical-trial/asc-us-population-results.html

Clinical implications for the cobas® HPV Test from ATHENA in the ASC-US population

  • Comparable performance to the prior standard of testing in pooled hrHPV testing
  • Significantly improves upon other commercially available HPV tests by individually identifying HPV 16 and 18 while simultaneously detecting 12 other hrHPV genotypes as a pooled result
  • The absolute risk of ≥CIN2 was 31.5% among women who were HPV 16 positive
  • Pooled hrHPV negative women were at low risk of ≥CIN2
  • Women who were HPV 16 positive were more than twice as likely to have ≥CIN2 than those women who were pooled hrHPV positive

연결문서

CC Attribution-Noncommercial-Share Alike 4.0 International 별도로 명시하지 않을 경우, 이 페이지의 내용은 다음 라이선스에 따라 사용할 수 있습니다: CC Attribution-Noncommercial-Share Alike 4.0 International
840 B med/athena_hpv_trial.txt · 마지막으로 수정됨 2016/07/10 09:50 (바깥 편집) V_L